1. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews

   • Paul Posadzki
   • Leala Watson
   • Edzard Ernst

   Review Article 29 July 2012 Pages: 295 - 307

   

2. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)

   • L. Součková
   • R. Opatřilová
   • V. Šrámek

   Review Article 14 August 2012 Pages: 309 - 317

   

3. Medication prescribing in frail older people

   • Ruth E. Hubbard
   • M. Sinead O’Mahony
   • Kenneth W. Woodhouse

   Review Article 11 September 2012 Pages: 319 - 326

4. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers

   • Sebastian Härtter
   • Regina Sennewald
   • Jeffrey Friedman

   Clinical Trial Open access 11 July 2012 Pages: 327 - 339

   

5. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia

   • Liliana Grigore
   • Sara Raselli
   • Alberico L. Catapano

   Clinical Trial 10 July 2012 Pages: 341 - 346

6. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials

   • Xavier Castells
   • Ruth Cunill
   • Dolors Capellà

   CLINICAL TRIAL 16 September 2012 Pages: 347 - 356

   

7. The out-of-focus bias in drug surveillance

   • Markus Gnädinger
   • Hans-Ulrich Mellinghoff

   Special Article 16 August 2012 Pages: 357 - 359

   

8. First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam

   • Paul I. Dargan
   • Susannah Davies
   • David M. Wood

   Pharmacodynamics 29 July 2012 Pages: 361 - 363

9. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study

   • I. L. Meek
   • H. E. Vonkeman
   • M. A. F. J. van de Laar

   Pharmacodynamics 14 August 2012 Pages: 365 - 371

   

10. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201

    • David McQuade
    • Simon Hudson
    • David M. Wood

    Pharmacodynamics 31 August 2012 Pages: 373 - 376

11. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients

    • Biljana Jekic
    • Ljiljana Lukovic
    • Maja Krajinovic

    Pharmacogenetics 05 July 2012 Pages: 377 - 383

12. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients

    • Montserrat García
    • Rosa María Macías
    • Guillermo Gervasini

    Pharmacogenetics 11 August 2012 Pages: 385 - 393

13. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population

    • T. Rusdiana
    • T. Araki
    • K. Yamamoto

    Pharmacogenetics 02 August 2012 Pages: 395 - 405

    

14. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers

    • Yu Cheng
    • Guo Wang
    • Hong-Hao Zhou

    Pharmacogenetics 28 July 2012 Pages: 407 - 413

    

15. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population

    • K. Subraja
    • S. A. Dkhar
    • C. Adithan

    Pharmacogenetics 06 September 2012 Pages: 415 - 422

    

16. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent

    • Frances Stringer
    • Graham Scott
    • Richard Urquhart

    Pharmacogenetics 09 September 2012 Pages: 423 - 430

    

17. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis

    • Diana Lacruz-Guzmán
    • Daniel Torres-Moreno
    • Pablo Conesa-Zamora

    Pharmacogenetics 08 September 2012 Pages: 431 - 438

    

18. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

    • Sara K. Quinney
    • Srikar R. Malireddy
    • Stephen D. Hall

    Pharmacokinetics and Disposition 10 July 2012 Pages: 439 - 448

    

19. Decreased vancomycin clearance in patients with congestive heart failure

    • Yuko Shimamoto
    • Tsuyoshi Fukuda
    • Katsuya Komori

    Pharmacokinetics and Disposition 12 July 2012 Pages: 449 - 457

    

20. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation

    • A. Richardson
    • K. S. Sakariassen
    • A. S. Sorensen

    Pharmacokinetics and Disposition 20 July 2012 Pages: 459 - 465

    

21. VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation

    • Milka Marinova
    • Dieter Lütjohann
    • Johannes Oldenburg

    Pharmacokinetics and Disposition Open access 05 August 2012 Pages: 467 - 475

    

22. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers

    • Renli Teng
    • Patrick D. Mitchell
    • Kathleen A. Butler

    Pharmacokinetics and Disposition 25 August 2012 Pages: 477 - 487

    

23. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers

    • Jun Tanaka
    • Hidefumi Kasai
    • Yuji Kumagai

    Pharmacokinetics and Disposition Open access 24 August 2012 Pages: 489 - 497

    

24. Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach

    • Sihem Benaboud
    • Saïk Urien
    • Marie Courbebaisse

    Pharmacokinetics and Disposition 31 August 2012 Pages: 499 - 506

    

25. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity

    • Ines Fuchs
    • Verena Hafner-Blumenstiel
    • Gerd Mikus

    Pharmacokinetics and Disposition 12 September 2012 Pages: 507 - 513

    

26. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers

    • Miao Yan
    • Ping-Fei Fang
    • Qin-You Tan

    Pharmacokinetics and Disposition 15 September 2012 Pages: 515 - 521

    

27. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects

    • Matthias Hoch
    • Petra Hoever
    • Jasper Dingemanse

    Pharmacokinetics and Disposition 19 September 2012 Pages: 523 - 532

    

28. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

    • P. H. Cashin
    • H. Ehrsson
    • H. Mahteme

    Pharmacokinetics and Disposition 16 September 2012 Pages: 533 - 540

    

29. In utero exposure to antidepressants and the use of drugs for pulmonary diseases in children

    • P. G. J. ter Horst
    • H. J. Bos
    • B. Wilffert

    Pharmacoepidemiology and Prescription Open access 20 July 2012 Pages: 541 - 547

30. High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications

    • E. Garbe
    • S. Kloss
    • S. Schneeweiss

    Pharmacoepidemiology and Prescription 05 July 2012 Pages: 549 - 557

    

31. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

    • L. H. Martín Arias
    • C. Treceño
    • A. Carvajal

    Pharmacoepidemiology and Prescription 21 July 2012 Pages: 559 - 564

    

32. Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care

    • M. L. Andersson
    • Y. Böttiger
    • B. Eiermann

    Pharmacoepidemiology and Prescription 01 July 2012 Pages: 565 - 571

    

33. Medication complexity, prescription behaviour and patient adherence at the interface between ambulatory and stationary medical care

    • Dorit Stange
    • Levente Kriston
    • Dorothee C. Dartsch

    Pharmacoepidemiology and Prescription 25 July 2012 Pages: 573 - 580

    

34. Prescription drug dispensing profiles for one million children: a population-based analysis

    • Tingting Zhang
    • M. Anne Smith
    • Bruce C. Carleton

    Pharmacoepidemiology and Prescription 12 July 2012 Pages: 581 - 588

    

35. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective

    • Anton Pottegård
    • Bine Kjøller Bjerregaard
    • Søren Ilsøe Moreno

    Pharmacoepidemiology and Prescription 19 July 2012 Pages: 589 - 598

    

36. Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies

    • Marco Sequi
    • Rita Campi
    • Maurizio Bonati

    Pharmacoepidemiology and Prescription 26 July 2012 Pages: 599 - 604

37. Methodology for a multinational case–population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT)

    • Sinem Ezgi Gulmez
    • Dominique Larrey
    • Nicholas Moore

    Pharmacoepidemiology and Prescription 10 August 2012 Pages: 605 - 616

    

38. Identification and weighting of the most critical “real-life” drug–drug interactions with acenocoumarol in a tertiary care hospital

    • L. Gschwind
    • V. Rollason
    • J. A. Desmeules

    Pharmacoepidemiology and Prescription 19 August 2012 Pages: 617 - 627

39. Concurrent use of antiplatelets, anticoagulants, or digoxin with Chinese medications: a population-based cohort study

    • Hsin-Hui Tsai
    • Hsiang-Wen Lin
    • Tsai-Chung Li

    Pharmacoepidemiology and Prescription 09 August 2012 Pages: 629 - 639

    

40. Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case–control study

    • Anton Pottegård
    • Peter M. Meegaard
    • Jesper Hallas

    Pharmacoepidemiology and Prescription 31 July 2012 Pages: 641 - 646

41. In-hospital medication reviews reduce unidentified drug-related problems

    • Åsa Bondesson
    • Tommy Eriksson
    • Peter Höglund

    Pharmacoepidemiology and Prescription 07 September 2012 Pages: 647 - 655

    

42. Potentially inappropriate drug use among older persons in Finland: application of a new national categorization

    • J. Simon Bell
    • Jouni Ahonen
    • Sirpa Hartikainen

    Pharmacoepidemiology and Prescription 14 August 2012 Pages: 657 - 664

43. Different patterns in use of antibiotics for lower urinary tract infection in institutionalized and home-dwelling elderly: a register-based study

    • Ylva Haasum
    • Johan Fastbom
    • Kristina Johnell

    Pharmacoepidemiology and Prescription 25 August 2012 Pages: 665 - 671

    

44. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority

    • Inês Ribeiro-Vaz
    • Joana Marques
    • Eva Rebelo Gomes

    Pharmacoepidemiology and Prescription 23 August 2012 Pages: 673 - 681

    

45. The association of ethnicity with electronically measured adherence to inhaled corticosteroids in children

    • Erwin Vasbinder
    • Nordin Dahhan
    • Patricia van den Bemt

    Pharmacoepidemiology and Prescription 07 September 2012 Pages: 683 - 690

    

46. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case–control study in a new general practice database

    • Francisco J. de Abajo
    • Miguel J. Gil
    • Luis A. García-Rodríguez

    Pharmacoepidemiology and Prescription 06 September 2012 Pages: 691 - 701

    

47. Application of the MAT-CHD_SP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention

    • Beate Hennie Garcia
    • Lars Småbrekke
    • Trude Giverhaug

    Pharmacoepidemiology and Prescription 19 September 2012 Pages: 703 - 709

48. Placebo? no thanks, it might be bad for me!

    • Silvio Garattini
    • Vittorio Bertelé
    • Rita Banzi

    Point of View 16 September 2012 Pages: 711 - 714

49. Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden

    • Carlo Piccinni
    • Emanuel Raschi
    • Fabrizio De Ponti

    Short Communication 01 September 2012 Pages: 715 - 720

    

50. A probable clinically significant interaction between warfarin and cloxacillin: three case reports

    • Hossein Khalili
    • Naemeh Nikvarz
    • Simin Dashti-Khavidaki

    Short Communication 04 September 2012 Pages: 721 - 724